Additional Speakers

For the full program, click here

For plenary speakers, click here

For additional speakers, click here​


Surname First name Country Abstract Title
AubertIsabelleCanadaFOCUSED ULTRASOUND APPLICATIONS FOR THE TREATMENT OF ALZHEIMER’S DISEASE
AufschnaiterAndreasAustriaTRAFFIC JAM: IMPAIRMENT OF AUTOPHAGY AND ENDOCYTIC PATHWAYS BY THE PARKINSON’S DISEASE ASSOCIATED PROTEIN LRRK2 IN AGEING YEAST
BalducciClaudiaItalyMESENCHYMAL STEM CELL-DERIVED SECRETOME REDUCES PLAQUE DEPOSITION AND MICROGLIA ACTIVATION IN ASSOCIATION TO MEMORY IMPROVEMENT IN APP/PS1 ALZHEIMER’S DISEASE MICE
BalinBrianUSAPROOF OF CONCEPT STUDIES OF CHLAMYDIA PNEUMONIAE INFECTION AS A TRIGGER FOR LATE-ONSET ALZHEIMER DISEASE
BannachOliverGermanyHOMO- AND HETERO-AGGREGATES AS BIOMARKERS IN NEURODEGENERATIVE DISEASES
BarendrechtSusanGermanyIMPROVEMENT OF THE MICROGLIAL PHENOTYPE IN VITRO FOR BETTER INVESTIGATION OF THE ROLE OF MICROGLIA IN ALZHEIMER’S DISEASE
BasaiaSilviaItalySTRUCTURAL AND FUNCTIONAL BRAIN CONNECTOME ARCHITECTURE IN ALZHEIMER’S DISEASE AND AMNESIC MILD COGNITIVE IMPAIRMENT PATIENTS
Ben-GedalyaTzionaIsraelPRESENILIN1 FUNCTIONAL CONFORMATION REQUIRES ASSISTANCE OF CYCLOPHILIN B FOLDING CHAPERONES
Blanca RamirezMarianSpainGTP BINDING REGULATION OF CELLULAR LOCALIZATION OF PARKINSON'S DISEASE ASSOCIATED LRRK2
BoonBaaylaNetherlandsDISTRIBUTION OF TAU PATHOLOGY AND NEUROINFLAMMATION IN TYPICAL VERSUS ATYPICAL ALZHEIMER’S DISEASE
BradshawElizabethUSASMALL MOLECULE SCREENING OF HUMAN PBMCS TO IDENTIFY COMPOUNDS THAT CORRECT THE FUNCTIONAL CONSEQUENCES OF THE CD33 ALZHEIMER’S DISEASE RISK ALLELE
BrinkmalmAnnSwedenA NOVEL AFFINITY PROTEOMICS ASSAY ALLOWS PARALLEL QUANTITATION OF SNAP-25 AND SYNAPTOTAGMIN-1IN HUMAN CEREBROSPINAL FLUID.
BrintonRobertaUSAALLOPREGNANOLONE AS A REGENERATIVE THERAPEUTIC FOR ALZHEIMER'S DISEASE: PHASE 1B/2A UPDATE
BroersenKerensaThe NetherlandsBLOOD-BRAIN BARRIER PERMEABLE NANOPARTICLE AIDED INCLUSION OF A THERAPEUTIC DRUG COCKTAIL FOR ALZHEIMER'S DISEASE
BrownjohnPhilipUnited KingdomCONSEQUENCES OF TREM2 MUTATIONS IN IPSC-DERIVED MICROGLIA-LIKE CELLS
BushWilliamUSAIN SILICO FUNCTIONAL ANNOTATION OF GENOMIC VARIANTS FOR NEURODEGENERATIVE DISEASE
ChiangCarlUSAIMPLEMENTATION OF MCI DUE TO AD AS A NOVEL ENDPOINT EVENT IN A DELAY OF ONSET PHASE 3 CLINICAL TRIAL
ChiesaRobertoItalyINDUCTION OF TRANSMISSIBLE TAU PATHOLOGY BY TRAUMATIC BRAIN INJURY
ClarkeEmilyUnited KingdomTHE LINK BETWEEN MUTANT GLUCOCEREBROSIDASE AND LEWY BODY DEMENTIAS (LBDS) – THE UNFOLDED PROTEIN RESPONSE
ComerotaMicheleUSANEAR INFRARED LIGHT INDUCES SYNAPTIC RESISTANCE TO THE DYSFUNCTIONAL BINDING OF TOXIC AMYLOID BETA OLIGOMERS
Darreh-ShoriTaherSwedenEMERGING NEW LIGANDS OF CHOLINERGIC ENZYMES- POTENTIAL AS THERAPEUTICS, IN VIVO FUNCTIONAL BIOMARKERS AND DEMENTIA RISK FACTORS
DemonetJean-FrancoisSwitzerlandAUTOMATED PREDICTION OF TYPICAL AND MIXED ALZHEIMER’S DISEASE USING COMBINED ROUTINE BRAIN VOLUMETRY AND COGNITIVE ASSESSMENT
DioliChrysoulaPortugalTHE CYTOSKELETAL PROTEIN TAU AS A KEY ELEMENT IN STRESS-INDUCED SUPPRESSION OF ADULT HIPPOCAMPAL NEUROGENESIS
DongYuanFrancePHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF NEUTROPHILS IN ALZHEIMER DISEASE : ASSOCIATION WITH DISEASE SEVERITY
Duran-AniotzClaudiaChileTARGETING IRE1 IN THE NERVOUS SYSTEM REDUCES ALZHEIMER'S DISEASE PATHOGENESIS
EscartinCaroleFranceMODULATION OF ASTROCYTE REACTIVITY VIA THE JAK2-STAT3 PATHWAY REVEALS CONTEXT-DEPENDENT EFFECTS IN MOUSE MODELS OF ALZHEIMER’S DISEASE
FarottiLuciaItalyCSF A BETA 42/ A BETA 40 RATIO IMPROVES THE DIFFERENTIAL DIAGNOSIS BETWEEN ALZHEIMER’S DISEASE AND FRONTOTEMPORAL DEMENTIA COMPARED TO A BETA 42 ALONE
FonarGennadiyIsraelMODIFIED SNAKE Α-NEUROTOXINS ENHANCE MEMORY OF ALZHEIMER'S DISEASE MICE
FranthalSebastianAustriaDYNAMICS OF BRAIN IRON LEVELS IN PARKINSON'S DISEASE AND NON-DEGENERATIVE TREMORS
FuhrmannMartinGermanySOMATOSTATIN-POSITIVE INTERNEURONS AND THEIR RELATION TO MEMORY DEFICITS IN A MOUSE MODEL OF ALZHEIMER'S DISEASE
GalantucciSebastianoItalyFUNCTIONAL CONNECTOME ORGANIZATION IS ALTERED IN PD PATIENTS WITH MILD COGNITIVE IMPAIRMENT
GibbsEbrimaCanadaRATIONAL GENERATION OF AΒ OLIGOMER-SPECIFIC ANTIBODIES THROUGH COMPUTATIONAL IDENTIFICATION OF CONFORMATIONAL EPITOPES
GloireMélanieBelgiumRECIPROCAL INFLUENCE BETWEEN APP EXPRESSION AND GLUCOSE METABOLISM IN THE HIPPOCAMPUS
GozesIllanaIsraelA NOVEL TARGET AGAINST TAUOPATHY: PROTECTION OF DYNAMIC MICROTUBULES BY ENHANCEMENT OF TAU-MICROTUBULE-END BINDING PROTEIN INTERACTION
GriffinSueUSASPECIFIC BINDING OF THE CLEAR MOTIF BY APOE4 FOILS AUTOPHAGY OF AGGREGATES
GuoTongUnited KingdomMOLECULAR MECHANISMS UNDERLYING THE DEVELOPMENT OF TAU PATHOLOGY CAUSED BY N-TERMINAL TAU FRAGMENTATION
HallbeckMartinSwedenSPREAD OF ALZHEIMER’S DISEASE COULD BE CAUSED BY EXOSOMES FILLED WITH TOXIC AMYLOID-BETA OLIGOMERS
HassenstabJasonUSARELIABILITY AND REPRODUCIBILITY OF COGNITIVE COMPOSITES FOR ALZHEIMER'S DISEASE SECONDARY PREVENTION TRIALS: THE POWER-PACC
Hernandez GuillamonMarSpainRECOMBINANT APOA-I MILANO VARIANT REDUCES CEREBRAL Β-AMYLOID ACCUMULATION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE
HorváthAndrásHungaryPREVALENCE, RISK FACTORS AND IMPACT OF ALZHEIMER’S- RELATED EPILEPSY
IijimaKoichi M.JapanECTOPIC EXPRESSION OF HUMAN TREM2/TYROBP IN DROSOPHILA GLIAL CELLS NEGATIVELY AFFECTS TRANSCRIPTIONAL PROGRAMS INDUCED BY ABETA42 AND WORSENS TAU-MEDIATED NEURODEGENERATION
JanAsadCanadaEEF2K INHIBITION BLOCKS AΒ42 NEUROTOXICITY BY PROMOTING AN NRF2 ANTIOXIDANT RESPONSE
JanelidzeShorenaSwedenINCREASED CEREBROSPINAL FLUID/PLASMA ALBUMIN RATIO, AN INDICATOR OF BLOOD-BRAIN BARRIER PERMEABILITY, IS ASSOCIATED WITH DEMENTIA AND DIABETES BUT NOT AMYLOID PATHOLOGY OR APOE GENOTYPE.
JendrachMarinaGermanyAUTOPHAGY INFLUENCES THE INFLAMMATORY RESPONSE OF MICROGLIA IN ALZHEIMER’S DISEASE
JohanssonJanneSwedenINTERACTIONS BETWEEN BRICHOS PROTEINS AND AΒPP / AΒ42 IN PRIMARY NEURONS – IS BRICHOS A CHAPERONE FOR AΒ?
JosephMariaGermanyNEUROGENIC EFFECT OF THE ANTI-AGGREGANT TAU REPEAT DOMAIN IN THE HIPPOCAMPUS
KangMin Su (Peter)CanadaHIPPOCAMPAL METABOLIC NETWORK SERVES AS A TRANSLATIONAL BIOMARKER OF ALZHEIMER'S DISEASE: INTERSPECIES STUDY
KangJi YoonRepublic of KoreaBLOOD-BASED DIAGNOSIS OF ALZHEIMER’S DISEASE BASED ON THE OLIGOMER TO MONOMER RATIO OF AMYLOID ΒETA IN NEURONAL EXOSOME
Kienlen-CampardPascalBelgiumSTRUCTURAL MOTIFS FROM APP TRANSMENRANE REGION COMPETE FOR DIMERIZATION AND AΒ OLIGOMERIZATION
KimYeshinRepublic of KoreaEFFECTS OF EDUCATION ON RESTING STATE FUNCTIONAL CONNECTIVITY AND COGNITION IN SUBJECTS WITH NORMAL COGNITION AND ALZHEIMER’S DEMENTIA
KoivistoAnneFinlandVENTRICULAR ENLARGEMENT IS ASSOCIATED WITH HIGH RISK OF DEMENTIA - 5-YEAR FOLLOW-UP STUDY
KuiperijBeaThe NetherlandsVALIDATION OF MICRORNAS IN CEREBROSPINAL FLUID AS BIOMARKERS FOR DIFFERENT FORMS OF DEMENTIA IN A MULTICENTER STUDY
LaiRobertUnited KingdomE2609, A NOVEL BACE1 INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY BETWEEN JAPANESE AND WHITE SUBJECTS
LashleyTammarynUnited KingdomCOMPARISONS OF PATHOLOGICAL CHANGES BETWEEN AMNESTIC ALZHEIMER’S DISEASE AND POSTERIOR CORTICAL ATROPHY
LawsSimonAustraliaGENETIC RISK PROFILE FOR PREDICTION OF COGNITIVE DECLINE IN PRE-SYMPTOMATIC AD CLINICAL TRIALS
LiLingUSADYSREGULATION OF PROTEIN PRENYLATION AND RAS/ERK SIGNALING IN ALZHEIMER’S DISEASE
MarinRaquelSpainESTROGEN RECEPTOR SIGNALOSOMES IN FRONTAL CORTEX ARE ALTERED DURING MENOPAUSE, A PHENOMENON INDUCING TOXIC SIGNALLING AND ENSUING ALZHEIMER’S DISEASE
McInnesJosephBelgiumTHE N-TERMINUS OF TAU MEDIATES DEFECTS IN PRESYNAPTIC FUNCTION VIA DIRECT ASSOCIATION WITH SYNAPTIC VESICLES
MenneFelixGermanyNEUROPSYCHOMETRIC TESTS VALIDATED BY CSF-BIOMARKERS TO DETECT AD PATHOLOGY IN PATIENTS PRESENTING WITH DEPRESSIVE SYMPTOMS
MilenkovicIvanAustriaTHE PHYSIOLOGIC PHOSPHORYLATION OF TAU IS CRITICALLY CHANGED IN FETAL BRAINS OF INDIVIDUALS WITH DOWN SYNDROME
MisitiFrancescoItalyROLE OF RED BLOOD CELLS IN VASCULAR DYSFUNCTION-ASSOCIATED WITH ALZHEIMER S DISEASE
MolineroCésarSpainFIRST-IN-MAN CLINICAL TRIAL TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ORY-2001, A NOVEL EPIGENETIC DRUG FOR TREATMENT OF NEURODEGENERATIVE DISEASE.
MurrayChristinaUnited KingdomGENETIC AND PROTEOMIC PROFILING OF SPORADIC AND FAMILIAL ALZHEIMER'S DISEASE POST-MORTEM BRAINS
NaelVirginieFranceVISUAL LOSS AND 12 YEARS RISK OF DEMENTIA IN OLDER ADULTS: A FRENCH POPULATION-BASED COHORT STUDY
Nagel-StegerLuitgardGermanyAΒETA(1-42) PENTAMERS/HEXAMERS ARE THE SMALLEST DETECTABLE OLIGOMERS IN SOLUTION
NationGrantUSAASSOCIATION OF PATHOLOGICAL TAU WITH RIBOSOMES IMPAIRS FUNCTION AND DECREASES PROTEIN SYNTHESIS
OkunEitanIsraelASSESSING THE EFFICACY OF A DNA VACCINE AGAINST AMYLOID-Β IN A DOWN-SYNDROME MOUSE MODEL
OrtnerMarionGermanyTRANSCRANIAL DOPPLER ULTRASOUND - A PROMISING NON-INVASIVE BIOMARKER FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE
PaoPing-ChiehUSALOSS OF HDAC1 AGGRAVATES BRAIN AGING
Paula-LimaAndreaChileFIXATION-RELATED POTENTIALS AND VISUAL EXPLORATION DURING A VIRTUAL WATER MAZE TASK  IN AGING AND EARLY ALZHEIMER´S DISEASE
PetersFinnGermanyPHARMACOLOGICAL INHIBITION OF BACE1 REDUCES AMYLOID AND PRESYNAPTIC PATHOLOGY IN TRANSGENIC ALZHEIMER MICE
PillaiJaganUSACOMPARISON OF FDG BRAIN PET OCCIPITAL HYPOMETABOLISM, PRESERVATION OF POSTERIOR CINGULATE AND AMYGDALA REGIONAL METABOLISM IN DEMENTIA WITH LEWY BODIES IN A MEMORY CLINIC
Pinkas-KramarskiRonitIsraelAUTOPHAGY IN NEURODEGENERATION.
RabeyJose M.IsraelREPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) COMBINED WITH COGNITIVE TRAINING (RTMS-COG) IS EFFECTIVE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
RiceHeatherBelgiumAMYLOID PRECURSOR PROTEIN IS A MODULATOR OF GABA(B) RECEPTOR SIGNALING
RussoMirellaItalyCOMBINED MRI BRAIN AUTOMATED SEGMENTATION, CSF BIOMARKERS, NEUROPSYCHOLOGICAL STANDARD BATTERY AND CANTAB IN A MCI COHORT: AN EXPLORATORY STUDY
SalmonEricBelgiumMAPPING BRAIN SYNAPSES WITH PET AND [18F]UCB-H, A TRACER FOR SYNAPTIC VESICLE PROTEIN 2A
SaracenoClaudiaItalyTHE RHOLE OF RHO-GTPASES IN THE AETIOLOGY OF ALZHEIMER'S DISEASE
SchartmannAnna ElenaGermanyRAISING AVAILABLE BRAIN CONCENTRATIONS OF A POTENTIAL ALZHEIMER’S DISEASE DRUG CANDIDATE BY PEPTIDE CYCLIZATION
SchmidAdrian WilhelmSwitzerlandUNDERSTANDING THE MOLECULAR MECHANISMS OF BETA-AMYLOID PEPTIDE OLIGOMERIZATION ALLOWS FOR AN ANTIBODY SPECIFIC TARGETING OF DIMERS AND TRIMERS IN HUMAN AD BRAINS AND CSF
SegalDanielIsraelNEGATIVE CORRELATION BETWEEN PATHWAYS OF O-GLCNACYLATION AND N-/O-GLYCOSYLATION IN THE BRAIN OF ALZHEIMER'S DISEASE PATIENTS
SeibylJohnUSAFIRST IN HUMAN CHARACTERIZATION OF PI-2620, A NEXT GENERATION PET TRACER FOR ASSESSING TAU IN ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES
SimoneRobertoUnited KingdomANTISENSE LONG NON-CODING RNA REPRESSES MAPT TRANSLATION THROUGH AN EMBEDDED MIR REPEAT
StomrudErikSwedenCOMPARISON OF DIFFERENT PRE-ANALYTICAL PROTOCOLS USED FOR CSF HANDLING IN LARGE ALZHEIMER’S DISEASE COHORTS
StorckSteffenGermanyLRP1 MEDIATES AMYLOID TRANSPORT ACROSS CNS BARRIERS
TatenhorstLarsGermanyTHE ROCK INHIBITOR FASUDIL AFFECTS ALPHA SYNUCLEIN AGGREGATION AND SPREADING IN MODELS OF PARKINSON’S DISEASE IN VITRO AND IN VIVO
TheofilasPanosUSACELL DEATH PATHWAYS MEDIATING NEURONAL LOSS DURING ALZHEIMER’S DISEASE PROGRESSION IN HUMANS
TomitaTaisukeJapanLOSS OF ASTROCYTE-DERIVED KALLIKREIN 7 EXACERBATES AMYLOID PATHOLOGY AND NEURITIC CHANGE IN ALZHEIMER DISEASE
TomiyamaTakamiJapanANTIBIOTIC RIFAMPICIN IS A CANDIDATE PREVENTIVE MEDICINE FOR DEMENTIA: ITS ACTIONS AGAINST AΒ AND TAU OLIGOMERS
TramutolaAntonellaItalyPOLYUBIQUITOME PROFILE IN ALZHEIMER HUMAN BRAIN
Van KeerKarelBelgiumOPTICAL COHERENCE TOMOGRAPHY IN CEREBRAL AMYLOIDOSIS
WangYipengGermanyTHE RELEASE AND TRANS-SYNAPTIC TRANSMISSION OF TAU VIA EXOSOMES
WeimerRobbyUSAEVALUATION OF BASELINE AND LONGITUDINAL TAU PATHOLOGY IN ALZHEIMER’S DISEASE USING [18F]GTP1 (GENENTECH TAU PROBE 1) PET IMAGING
WhyteLaurenAustraliaLYSOSOMAL NETWORK FUNCTION IN ALZHEIMER’S DISEASE: A COMPARISON OF HUMAN TISSUE AND A KNOCK-IN MOUSE MODEL
YangHuiChinaAGE-DEPENDENT ALPHA-SYNUCLEIN ACCUMULATION IS CORRELATED WITH ELEVATION OF MITOCHONDRIAL TRPC3 IN THE BRAINS OF MONKEYS AND MICE


AD/PD™ Facebook
AD/PD™ Twitter
AD/PD™ Network

Keep Me Updated